v3.26.1
Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2026
Stock-Based Compensation  
Schedule of stock option activity

Weighted

Weighted

Average

Average

Exercise

Remaining

Price

Contractual

  ​ ​ ​

Shares

  ​ ​ ​

Per Share

  ​ ​ ​

Term (In Years)

Options outstanding at December 31, 2025

 

9,134,278

$

26.49

7.1

Granted

 

2,588,670

$

33.83

Exercised

 

(41,894)

$

22.30

Canceled

 

(250,328)

$

42.97

Options outstanding at June 30, 2026

 

11,430,726

$

27.80

7.5

Options vested and expected to vest at June 30, 2026

 

11,288,830

$

27.77

7.4

Options exercisable at June 30, 2026

 

6,194,728

$

25.60

6.0

Shares available for grant under the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (as amended, effective as of June 25, 2026) at June 30, 2026

 

3,686,494

Schedule of stock-based compensation expense

Three Months Ended June 30, 

Six Months Ended June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

(In thousands)

(In thousands)

Research and development

$

4,588

$

4,882

$

9,235

$

9,467

General and administrative

 

3,820

 

4,309

 

7,696

 

9,040

Total stock-based compensation expense

$

8,408

$

9,191

$

16,931

$

18,507

Schedule of assumptions used for the fair value of employee stock options granted

Three Months Ended June 30, 

Six Months Ended June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Expected stock price volatility

 

63 – 74%

76%

63 – 76%

76 – 81%

Expected option term

 

6.0 Years

6.0 Years

6.0 Years

6.0 Years

Risk-free interest rate

 

4.0 – 4.4%

4.1 – 4.3%

3.8 – 4.4%

4.1 – 4.7%

Expected dividend yield

 

None

None

None

None